Seeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage. The purpose of this profile is to allow us to share with our readers new transcript-related developments. Thanks, SA Transcripts Team ...

- Second-generation constructs induce robust increases in fecal IgA, which was shown to be correlated with protection against infection in the company’s previous Phase 2b challenge study - SOUTH SAN FRANCISCO, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today reported additional positive data from the Phase 1 clinical trial evaluating its second-g ...

Vaxart FY Conference Summary Company Overview - **Company**: Vaxart (NasdaqCM: VXRT) - **Industry**: Biopharmaceuticals, specifically vaccine development Core Points and Arguments 1. **Vaccine Platform**: Vaxart is developing an oral pill vaccine platform that aims to provide both systemic and mucosal immunity, presenting a potential alternative to traditional injectable vaccines [2][3][4] 2. **Thermal Stability**: The oral pill vaccine is thermally stable, facilitating easier administration and distribution, with all manufacturing conducted in the United States [3][4][21] 3. **Current Vaccine Candidates**: Vaxart is working on vaccines for norovirus, COVID-19, flu, and potentially human papillomavirus (HPV) in the future [2][5][21] 4. **Norovirus Vaccine**: - The economic burden of norovirus exceeds $10 billion annually, with no approved vaccines currently available [6] - Vaxart's bivalent vaccine targets dominant strains GII.1 and GII.4, showing promise in reducing infection rates [7][9] - Phase 2 challenge study results indicated a 30% relative reduction in infections compared to placebo [10] - A next-generation vaccine candidate is set to progress to phase 2B trials, with discussions ongoing for potential partnerships and funding [12][18] 5. **COVID-19 Vaccine**: - A head-to-head study against an approved mRNA vaccine is ongoing, with 5,000 subjects enrolled in a BARDA-funded phase 2B clinical trial [12][13] - The trial aims to establish safety and tolerability, with a 12-month efficacy endpoint expected in the second half of 2026 [14][19] 6. **Flu Vaccine**: - Previous phase 2 challenge studies showed Vaxart's oral vaccine provided a 49% reduction in influenza infection compared to placebo, outperforming a leading injectable vaccine [17] - The company is also exploring a vaccine for avian flu (H5N1), with promising preclinical animal data [16][18] Additional Important Content 1. **Management Team**: Vaxart's leadership includes experts with extensive experience in vaccine development and manufacturing, emphasizing the company's strong foundation [20] 2. **Market Opportunity**: Vaxart positions itself as a pioneer in the vaccine space, particularly in addressing unmet medical needs with its innovative oral vaccine platform [18][21] 3. **Funding and Milestones**: The company is focused on securing funding to advance its vaccine candidates through clinical trials, with a cash runway extending to the first quarter of the following year [18][19] This summary encapsulates the key insights from Vaxart's FY conference, highlighting the company's innovative approach to vaccine development and its strategic focus on addressing significant health challenges.

Meeting adjourned to September 19, 2025 at 8:30 a.m. Pacific Time Adjournment provides stockholders with more time given changes in Board composition, additional governance change considerations and future potential disclosures Vaxart encourages all stockholders of record on July 29, 2025 who have not yet voted to do so by 11:59 p.m. Eastern Time on September 18, 2025 SOUTH SAN FRANCISCO, Calif., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (“Vaxart” or the “Company”) announced today that ...

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- SOUTH SAN FRANCISCO, Calif., September 2, 2025 — Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced that management will present at the H.C. Wainwright Global Investment Conference taking place September 8-10, 2025. Presentation Details:Date and Time: Monday, September 8 at 12:00 PM ETWebcast: Click Here A live webcas ...

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced that its Chairman, Michael J. Finney, Ph.D., has announced his retirement from the Company's Board of Directors and Science and Technology Committee after a distinguished tenure of service. His retirement will be effective September 30, 202 ...

ATLANTA, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Richard John Burgess, Daniel P. Houle, Michael Patrick Kelley, Marc Eustace Pereira, Patrice Raffy, Benjamin Sauv, Matthew M. Wallace, MD and David Whitney (collectively, the “Concerned Vaxart Stockholders”), who collectively beneficially own more than 2.5 million shares of Vaxart, Inc. (OTC: VXRT) (“Vaxart” or the “Company”) today urged fellow stockholders to vote “AGAINST” the Company’s proposed reverse stock split at the upcoming special meeting of stockholders ...

Core Viewpoint - Vaxart, Inc. has received approval from the Nasdaq Hearings Panel to implement a plan to regain compliance with Nasdaq's minimum bid price requirement, contingent upon completing a reverse stock split and demonstrating compliance by specified deadlines [1][2][5]. Group 1: Compliance Plan - The company must obtain stockholder approval for a reverse stock split by September 5, 2025, complete the reverse stock split by October 6, 2025, and demonstrate compliance with Nasdaq Listing Rule 5550(a)(2) by October 17, 2025 [2][3]. - Vaxart's management presented a compliance plan during a hearing on August 14, 2025, which included changes to the reverse stock split proposal, such as narrowing the proposed ratio and reducing the number of authorized shares [3]. Group 2: Stakeholder Engagement - The company is actively engaging with stockholders to address their questions and concerns, including a virtual fireside chat held on August 20, 2025 [4]. - CEO Steven Lo emphasized the importance of stockholder support for the reverse stock split to secure the company's future on Nasdaq [5]. Group 3: Company Overview - Vaxart is a clinical-stage biotechnology company focused on developing oral recombinant vaccines using a proprietary delivery platform, which allows for storage and shipping without refrigeration [7]. - The company's vaccine development programs include candidates for coronavirus, norovirus, influenza, and a therapeutic vaccine for human papillomavirus (HPV) [7].

Core Viewpoint - Concerned Vaxart Stockholders are urging fellow stockholders to vote against the proposed reverse stock split at the upcoming special meeting, citing a pattern of the Board disregarding stockholder interests and making value-destructive capital allocation decisions [1][2]. Group 1: Board Accountability - The Concerned Vaxart Stockholders collectively own over 2.5 million shares and are demanding accountability from the Board, which has ignored stockholder votes in the past [1]. - At the 2025 Annual Meeting, four out of six directors did not receive majority support for re-election, and stockholders overwhelmingly opposed the reverse stock split [2]. - Despite stockholder discontent, all six directors remain on the Board and are seeking approval for a reverse stock split again, less than three months after the previous rejection [2]. Group 2: Threat to Stockholder Rights - The Board's historical behavior is seen as a direct threat to stockholder rights and jeopardizes the value of investments [3]. - There is skepticism regarding whether the reverse stock split, if approved, will be executed in a manner that benefits stockholders [3]. - Vaxart has conducted three discounted equity offerings in recent years, undermining stockholder value, including one after a significant funding announcement [3]. Group 3: Contradictory Actions - The Board has previously discussed pursuing non-dilutive funding, but subsequent capital raises have contradicted this commitment, raising concerns about the Board's dedication to protecting stockholder interests [4]. - The Concerned Vaxart Stockholders emphasize the need for stockholders to act now to defend their investments in the company's vaccination technology [5].

Core Viewpoint - Vaxart, Inc. is seeking stockholder support for a reverse stock split proposal, which has been endorsed by leading proxy advisory firms ISS and Glass Lewis [1][3]. Group 1: Company Overview - Vaxart is a clinical-stage biotechnology company focused on developing oral recombinant vaccines using a proprietary delivery platform [5]. - The company's vaccines are designed to be administered in pill form, eliminating the need for refrigeration and reducing the risk of needle-stick injuries [5]. - Current development programs include vaccines targeting coronavirus, norovirus, influenza, and a therapeutic vaccine for human papillomavirus (HPV) [5]. Group 2: Stockholder Engagement - The senior management team will host a virtual stockholder fireside chat on August 20, 2025, to address stockholder questions, particularly regarding the reverse stock split and Nasdaq compliance [2]. - Stockholders of record as of July 29, 2025, are encouraged to vote on the proposal by September 4, 2025 [4]. Group 3: Communication and Support - Investors can submit questions in advance of the conference call via email or through the webcast portal [3]. - A replay of the webcast will be available on the company's website after the event [3].